Clinical practice of personalized prophylaxis in hemophilia: Illustrations of experiences and benefits from two continents

Abstract

Key Clinical Message These cases of people with hemophilia (PWH) illustrate the importance of understanding the patient's expectations and desires and adapting treatment to meet these needs, in addition to traditional clinical targets. Population PK modeling and FVIII products with improved PK profiles provide the opportunity to individualize care and improve long‐term outcomes.

Clinical application of extended half‐life factor VIII in children with severe haemophilia A

“…At school age, the children usually have intravenous infusions 3 days a week. However, the protocol of prophylaxis is individualized as much as possible, based on age, venous access, bleeding phenotype, activity, and availability of clotting factor concentrates 10 …”

“…At school age, the children usually have intravenous infusions 3 days a week. However, the protocol of prophylaxis is individualized as much as possible, based on age, venous access, bleeding phenotype, activity, and availability of clotting factor concentrates 10. Almost 4 years ago, prophylaxis with EHL factor concentrates was implemented in our patients that led to fewer injections, improved treatment compliance for children and their families, as evaluated through the patients' records, satisfactory trough levels and better bleeding outcome.…”